Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Design Therapeutics

03/08/2026 12:43

Design Therapeutics Inc DSGN.OQ DSGN.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Design Therapeutics Inc is for a loss of 34 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Design Therapeutics Inc is $21.00, about 72.4% above its last closing price of $12.18
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.31
-0.33
-0.29
Beat
11.7
Dec. 31 2026
-0.41
-0.35
-0.27
Beat
23.7
Sep. 30 2025
-0.35
-0.34
-0.30
Beat
12.6​
Jun. 30 2025
-0.34
-0.33
-0.34
Missed
-3
​​Mar. 31 2025
-0.29
-0.28
-0.31
Missed
-10.7
Dec. 31 2024
-0.27
-0.24
Beat
10​
Sep. 30 2024
-0.22
-0.24
-0.23
Beat
5.5
Jun. 30 2024
-0.21
-0.23
-0.21
Beat
10
This summary was machine generated August 3 at 11:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)